CodeLab Capital（P990）株式概要CodeLab Capital ASは、ノルウェー国内および国際的な医療専門家向けにクラウド・ソリューションを提供しています。 詳細P990 ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性6/6配当金0/6報酬過去5年間の収益は年間0.6%増加しました。 リスク分析過去1年間で株主の希薄化は大幅に進んだ 意味のある時価総額がありません ( €7M )German市場と比較して、過去 3 か月間の株価の変動が非常に大きい意味のある収益がありません ( NOK11M )すべてのリスクチェックを見るP990 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW489,177 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeINBLROAG489,177 investors already sharing narrativesYour Fair Value€Current Price€0.3524.8k% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-155m209m2016201920222025202620282031Revenue NOK 479.4kEarnings NOK 55.7kAdvancedSet Fair ValueView all narrativesCodeLab Capital AS 競合他社ifa systemsSymbol: HMSE:IS8Market cap: €5.6mMeVis Medical SolutionsSymbol: XTRA:M3VMarket cap: €44.0mKontigo CareSymbol: DB:3KTMarket cap: €50.1mDocCheckSymbol: XTRA:AJ91Market cap: €58.3m価格と性能株価の高値、安値、推移の概要CodeLab Capital過去の株価現在の株価NOK 0.3552週高値NOK 0.3552週安値NOK 0.11ベータ0.681ヶ月の変化17.91%3ヶ月変化32.20%1年変化n/a3年間の変化-81.03%5年間の変化-98.58%IPOからの変化-99.08%最新ニュースお知らせ • May 01CodeLab Capital AS announced that it expects to receive NOK 18.8 million in funding from Agil Helse AS and other investor.CodeLab Capital AS announced a private placement to issue 4,700,000 common share at an issue price of NOK 4 for the proceeds of NOK 18,800,000 on April 29, 2026. The demand to subscribe for new shares has been received from the Company’s largest shareholders, Agil Helse AS, and new external investors. Investors that have signed the pre-commitment letters will be allocated at least NOK 17,000,000. Any issuance of new shares in the private placement is subject to the approval by the general meeting. Summons to the general meeting is expected to be sent at the latest by May 6,2026.Reported Earnings • Apr 24Full year 2025 earnings releasedFull year 2025 results: Revenue: kr10.8m (up kr10.6m from FY 2024). Net loss: kr14.9m (loss narrowed 90% from FY 2024).New Risk • Mar 17New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr38m free cash flow). Share price has been highly volatile over the past 3 months (23% average weekly change). Earnings have declined by 5.1% per year over the past 5 years. Shareholders have been substantially diluted in the past year (111% increase in shares outstanding). Revenue is less than US$1m (kr162k revenue, or US$17k). Market cap is less than US$10m (€3.64m market cap, or US$4.19m). Minor Risk Latest financial reports are more than 6 months old (reported June 2025 fiscal period end).お知らせ • Dec 30CodeLab Capital AS, Annual General Meeting, Jun 23, 2026CodeLab Capital AS, Annual General Meeting, Jun 23, 2026.お知らせ • Dec 29+ 4 more updatesCodeLab Capital AS to Report Fiscal Year 2025 Final Results on Apr 21, 2026CodeLab Capital AS announced that they will report fiscal year 2025 final results at 4:25 PM, Central European Standard Time on Apr 21, 2026Board Change • Nov 19No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. CEO & Chairman of the Board Anton Bondesen was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.最新情報をもっと見るRecent updatesお知らせ • May 01CodeLab Capital AS announced that it expects to receive NOK 18.8 million in funding from Agil Helse AS and other investor.CodeLab Capital AS announced a private placement to issue 4,700,000 common share at an issue price of NOK 4 for the proceeds of NOK 18,800,000 on April 29, 2026. The demand to subscribe for new shares has been received from the Company’s largest shareholders, Agil Helse AS, and new external investors. Investors that have signed the pre-commitment letters will be allocated at least NOK 17,000,000. Any issuance of new shares in the private placement is subject to the approval by the general meeting. Summons to the general meeting is expected to be sent at the latest by May 6,2026.Reported Earnings • Apr 24Full year 2025 earnings releasedFull year 2025 results: Revenue: kr10.8m (up kr10.6m from FY 2024). Net loss: kr14.9m (loss narrowed 90% from FY 2024).New Risk • Mar 17New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr38m free cash flow). Share price has been highly volatile over the past 3 months (23% average weekly change). Earnings have declined by 5.1% per year over the past 5 years. Shareholders have been substantially diluted in the past year (111% increase in shares outstanding). Revenue is less than US$1m (kr162k revenue, or US$17k). Market cap is less than US$10m (€3.64m market cap, or US$4.19m). Minor Risk Latest financial reports are more than 6 months old (reported June 2025 fiscal period end).お知らせ • Dec 30CodeLab Capital AS, Annual General Meeting, Jun 23, 2026CodeLab Capital AS, Annual General Meeting, Jun 23, 2026.お知らせ • Dec 29+ 4 more updatesCodeLab Capital AS to Report Fiscal Year 2025 Final Results on Apr 21, 2026CodeLab Capital AS announced that they will report fiscal year 2025 final results at 4:25 PM, Central European Standard Time on Apr 21, 2026Board Change • Nov 19No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. CEO & Chairman of the Board Anton Bondesen was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • May 28CodeLab Capital AS announced that it has received fundingCodeLab Capital AS announced a private placement transaction and it has issued 4799998 new shares on May 26, 2025.お知らせ • May 06CodeLab Capital AS (OB:CODE) signed an agreement to acquire 97.40% stake in Kuba Norge As for NOK 18.5 million.CodeLab Capital AS (OB:CODE) signed an agreement to acquire 97.40% stake in Kuba Norge As for NOK 18.5 million on May 5, 2025. The purchase price is NOK 20 million, to be paid as follows: one third of the purchase price shall be paid in cash at closing of the Transaction, one third of the purchase price shall be paid in kind through the issuance of 1,302,071 consideration shares in CodeLab at Closing, valued at NOK 5.12 per share, one third of the purchase price shall be deferred payment which falls due first quarter of 2028. The deferred payment is subject to adjustment depending on the development of the cash EBITDA of Kuba for 2027, but is capped at 1.5x the original deferred payment. Following the acquisition of Kuba Norge AS, CodeLab Capital AS is adjusting its leadership structure to align with its strategic direction. CEO Kristian Ikast will transition to the role of Chairman of the Board of Directors and continue as a close advisor to the company. CFO Christoffer Mathiesen will remain in his current role. Anton Lorenz Bondesen, the current Chairman of the Board, will become the CEO and will also continue as a member of the Board of Directors. The Transaction is subject to standard closing conditions, including the approval of the Company's shareholders in a general meeting for issuance of the Consideration Shares as well as certain other amendments to the share capital of the Company as described below. CodeLab Capital AS has secured approximately NOK 13.9 million in new equity funding for its acquisition of Kuba Norge AS, with contributions from leading shareholders such as Lorenz AS and Codee Holding AS, as well as other existing shareholders and external investors, including the sellers. The funding is at a subscription price of NOK 3.00 per share. CodeLab plans to conduct a private placement to complete the transaction, with a potential subsequent repair issue for minority shareholders. For the period ending December 31, 2024, Kuba Norge As reported total revenue of NOK 12.5 million. Advokatfirmaet Schjødt As acted as legal advisor to CodeLab Capital AS.お知らせ • Jan 24CodeLab Capital AS to Report Fiscal Year 2024 Results on May 15, 2025CodeLab Capital AS announced that they will report fiscal year 2024 results at 9:00 AM, Central European Standard Time on May 15, 2025お知らせ • Jan 02CodeLab Capital AS, Annual General Meeting, Jun 27, 2025CodeLab Capital AS, Annual General Meeting, Jun 27, 2025.お知らせ • Jan 01+ 1 more updateCodeLab Capital AS to Report Q4, 2025 Results on Feb 20, 2026CodeLab Capital AS announced that they will report Q4, 2025 results on Feb 20, 2026お知らせ • Jul 24Uniscale, Wholly-Owned Subsidiary of CodeLab Capital, Announces Peter Tuborgh Arnth Nielsen as New Head of Enterprise and PartnershipsUniscale, a wholly-owned subsidiary of CodeLab Capital, announced Peter Tuborgh Arnth Nielsen as the new Head of Enterprise and Partnerships, effective immediately. His role will be crucial in ensuring the growth and development of these strategically important areas of the business. Peter brings extensive experience in building long-term partnerships with international enterprises and large customers.New Risk • Mar 17New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr150m free cash flow). Shares are highly illiquid. Earnings have declined by 49% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (€18.4m market cap, or US$20.0m).Board Change • Mar 13No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.お知らせ • Oct 28CodeLab Capital AS to Report Q4, 2023 Results on Feb 23, 2024CodeLab Capital AS announced that they will report Q4, 2023 results on Feb 23, 2024お知らせ • May 19Jesper Melin Ganc-Petersen acquired an unknown minority stake in PatientSky Group AS.Jesper Melin Ganc-Petersen acquired an unknown minority stake in PatientSky Group AS on May 17, 2023.Jesper Melin Ganc-Petersen completed the acquisition of an unknown minority stake in PatientSky Group AS on May 17, 2023.Buying Opportunity • May 03Now 81% undervalued after recent price dropOver the last 90 days, the stock is down 65%. The fair value is estimated to be €0.20, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to decline by 0.7% per annum. Earnings is forecast to grow by 36% per annum over the same time period.Reported Earnings • Mar 06Full year 2022 earnings releasedFull year 2022 results: Revenue: kr194.5m (down 6.8% from FY 2021). Net loss: kr121.3m (loss widened 32% from FY 2021). Revenue is forecast to grow 2.1% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Healthcare Services industry in Europe.お知らせ • Jan 03+ 5 more updatesPatientSky Group AS to Report Q1, 2023 Results on May 25, 2023PatientSky Group AS announced that they will report Q1, 2023 results on May 25, 2023Reported Earnings • Nov 16Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: kr46.3m (down 10.0% from 3Q 2021). Net loss: kr29.3m (loss widened 69% from 3Q 2021). Revenue is forecast to stay flat during the next 3 years compared to a 9.9% growth forecast for the Healthcare Services industry in Europe.Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Investment Director & Director Sven Bakken was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 13Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: kr46.3m (down 11% from 3Q 2021). Net loss: kr29.3m (loss widened 5.1% from 3Q 2021). Revenue is forecast to stay flat during the next 3 years compared to a 9.8% growth forecast for the Healthcare Services industry in Europe.Reported Earnings • Aug 29Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: kr48.0m (down 6.7% from 2Q 2021). Net loss: kr22.9m (loss widened 26% from 2Q 2021). Over the next year, revenue is expected to shrink by 3.5% compared to a 16% growth forecast for the Healthcare Services industry in Germany.Buying Opportunity • Jul 01Now 26% undervalued after recent price dropOver the last 90 days, the stock is down 17%. The fair value is estimated to be €0.33, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 30% over the last year. Earnings per share has declined by 291%. For the next 3 years, revenue is forecast to decline by 2.4% per annum. Earnings is forecast to grow by 24% per annum over the same time period.Reported Earnings • May 21First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: kr50.1m (down 2.9% from 1Q 2021). Net loss: kr28.0m (loss widened 29% from 1Q 2021). Over the next year, revenue is forecast to grow 18%, compared to a 23% growth forecast for the industry in Germany.Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Sven Bakken was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Apr 10+ 2 more updatesPatientSky Group AS to Report First Half, 2022 Results on Aug 15, 2022PatientSky Group AS announced that they will report first half, 2022 results on Aug 15, 2022お知らせ • Apr 09PatientSky Group AS, Annual General Meeting, Jun 28, 2022PatientSky Group AS, Annual General Meeting, Jun 28, 2022.Reported Earnings • Feb 24Full year 2021 earnings: Revenues exceed analyst expectationsFull year 2021 results: Revenue: kr210.0m (up 50% from FY 2020). Net loss: kr79.4m (loss widened 239% from FY 2020). Revenue exceeded analyst estimates by 3.4%. Over the next year, revenue is forecast to grow 14%, compared to a 42% growth forecast for the industry in Germany.お知らせ • Feb 17PatientSky Group AS to Report Q4, 2021 Results on Feb 22, 2022PatientSky Group AS announced that they will report Q4, 2021 results on Feb 22, 2022Recent Insider Transactions • Sep 04Chief Commercial Officer recently bought €56k worth of stockOn the 1st of September, Egil Noen bought around 150k shares on-market at roughly €0.37 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold €48k more in shares than they bought in the last 12 months.お知らせ • Feb 19+ 2 more updatesPatientSky Group AS to Report First Half, 2021 Results on Sep 01, 2021PatientSky Group AS announced that they will report first half, 2021 results on Sep 01, 2021Is New 90 Day High Low • Feb 19New 90-day low: €1.08The company is down 17% from its price of €1.29 on 20 November 2020. The German market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare Services industry, which is up 5.0% over the same period.Recent Insider Transactions • Jan 30Co-founder & CTO recently sold €104k worth of stockOn the 27th of January, Andreas Kruger sold around 80k shares on-market at roughly €1.29 per share. This was the largest sale by an insider in the last 3 months. This was Andreas' only on-market trade for the last 12 months.お知らせ • Jan 28+ 1 more updatePatientSky Group AS Announces Executive AppointmentsPatientSky Group AS announced the appointment of Pelle Rosell as Chief Marketing Officer for PatientSky Group and Egil Natvik Noen as Chief Commercial Officer with responsibility for mobile apps.お知らせ • Dec 04PatientSky Group AS (OB:PSKY-ME) completed the acquisition of Infodoc AS and Acino AS.PatientSky Group AS (OB:PSKY-ME) entered into a conditional share purchase agreement to acquire Infodoc AS and Acino AS for an enterprise value of approx. NOK 280 million on November 9, 2020. The acquisition is of all the shares in Infodoc AS and Acino AS (collectively, Infodec) . The agreed enterprise value of Infodoc in the transaction is approx. NOK 280 million, on a cash-free and debt-free basis and assuming a normalised level of working capital. The purchase price under the transaction is, subject to customary adjustments, expected to be settled in cash upon closing. The completion of the acquisition is subject to customary closing conditions, including, without limitation, that the buyer shall have completed a due diligence review of Infodoc with a satisfactory result to the buyer (in its sole discretion), no material adverse change having occurred, required third party approvals being obtained as well as certain other conditions. The transaction is expected to close during Q4 2020. Advokatfirmaet Thommessen is acting as legal advisor to PatientSky. HLT Advokatfirma AS acted as legal advisor to Infodoc AS. PatientSky Group AS (OB:PSKY-ME) completed the acquisition of Infodoc AS and Acino AS on December 3, 2020.お知らせ • Nov 11PatientSky Group AS (OB:PSKY-ME) entered into a conditional share purchase agreement to acquire Infodoc AS and Acino AS for an enterprise value of approx. NOK 280 million.PatientSky Group AS (OB:PSKY-ME) entered into a conditional share purchase agreement to acquire Infodoc AS and Acino AS for an enterprise value of approx. NOK 280 million on November 10, 2020. The acquisition is of all the shares in Infodoc AS and Acino AS (collectively, Infodec) . The agreed enterprise value of Infodoc in the transaction is approx. NOK 280 million, on a cash-free and debt-free basis and assuming a normalised level of working capital. The purchase price under the transaction is, subject to customary adjustments, expected to be settled in cash upon closing. The completion of the acquisition is subject to customary closing conditions, including, without limitation, that the buyer shall have completed a due diligence review of Infodoc with a satisfactory result to the buyer (in its sole discretion), no material adverse change having occurred, required third party approvals being obtained as well as certain other conditions. The transaction is expected to close during Q4 2020. Advokatfirmaet Thommessen is acting as legal advisor to PatientSky.株主還元P990DE Healthcare ServicesDE 市場7D17.5%-0.8%0.6%1Yn/a14.3%1.1%株主還元を見る業界別リターン: P990がGerman Healthcare Services業界に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。リターン対市場: P990 German市場に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。価格変動Is P990's price volatile compared to industry and market?P990 volatilityP990 Average Weekly Movement23.7%Healthcare Services Industry Average Movement5.9%Market Average Movement5.6%10% most volatile stocks in DE Market13.4%10% least volatile stocks in DE Market2.7%安定した株価: P990の株価は、 German市場と比較して過去 3 か月間で変動しています。時間の経過による変動: P990の weekly volatility ( 24% ) は過去 1 年間安定していますが、依然としてGermanの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト201418Anton Bondesenwww.codelabcapital.comCodeLab Capital ASは、ノルウェー国内外の医療専門家向けにクラウドソリューションを提供している。ソフトウェア開発ツールを提供している。旧社名はPatientSky Group AS。同社は2014年に設立され、ノルウェーのオスロに本社を置く。もっと見るCodeLab Capital AS 基礎のまとめCodeLab Capital の収益と売上を時価総額と比較するとどうか。P990 基礎統計学時価総額€7.00m収益（TTM）-€1.32m売上高(TTM)€944.49k7.4xP/Sレシオ-5.3xPER（株価収益率P990 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計P990 損益計算書（TTM）収益NOK 10.66m売上原価NOK 11.83m売上総利益-NOK 1.17mその他の費用NOK 13.70m収益-NOK 14.88m直近の収益報告Dec 31, 2025次回決算日Aug 28, 2026一株当たり利益（EPS）-0.75グロス・マージン-11.02%純利益率-139.59%有利子負債／自己資本比率15.6%P990 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/01 11:50終値2026/07/01 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋CodeLab Capital AS 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Kristian StøleCarnegie Investment Bank ABOle-Andreas KrohnDNB CarnegieEmilie EngenDNB Carnegie
お知らせ • May 01CodeLab Capital AS announced that it expects to receive NOK 18.8 million in funding from Agil Helse AS and other investor.CodeLab Capital AS announced a private placement to issue 4,700,000 common share at an issue price of NOK 4 for the proceeds of NOK 18,800,000 on April 29, 2026. The demand to subscribe for new shares has been received from the Company’s largest shareholders, Agil Helse AS, and new external investors. Investors that have signed the pre-commitment letters will be allocated at least NOK 17,000,000. Any issuance of new shares in the private placement is subject to the approval by the general meeting. Summons to the general meeting is expected to be sent at the latest by May 6,2026.
Reported Earnings • Apr 24Full year 2025 earnings releasedFull year 2025 results: Revenue: kr10.8m (up kr10.6m from FY 2024). Net loss: kr14.9m (loss narrowed 90% from FY 2024).
New Risk • Mar 17New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr38m free cash flow). Share price has been highly volatile over the past 3 months (23% average weekly change). Earnings have declined by 5.1% per year over the past 5 years. Shareholders have been substantially diluted in the past year (111% increase in shares outstanding). Revenue is less than US$1m (kr162k revenue, or US$17k). Market cap is less than US$10m (€3.64m market cap, or US$4.19m). Minor Risk Latest financial reports are more than 6 months old (reported June 2025 fiscal period end).
お知らせ • Dec 30CodeLab Capital AS, Annual General Meeting, Jun 23, 2026CodeLab Capital AS, Annual General Meeting, Jun 23, 2026.
お知らせ • Dec 29+ 4 more updatesCodeLab Capital AS to Report Fiscal Year 2025 Final Results on Apr 21, 2026CodeLab Capital AS announced that they will report fiscal year 2025 final results at 4:25 PM, Central European Standard Time on Apr 21, 2026
Board Change • Nov 19No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. CEO & Chairman of the Board Anton Bondesen was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • May 01CodeLab Capital AS announced that it expects to receive NOK 18.8 million in funding from Agil Helse AS and other investor.CodeLab Capital AS announced a private placement to issue 4,700,000 common share at an issue price of NOK 4 for the proceeds of NOK 18,800,000 on April 29, 2026. The demand to subscribe for new shares has been received from the Company’s largest shareholders, Agil Helse AS, and new external investors. Investors that have signed the pre-commitment letters will be allocated at least NOK 17,000,000. Any issuance of new shares in the private placement is subject to the approval by the general meeting. Summons to the general meeting is expected to be sent at the latest by May 6,2026.
Reported Earnings • Apr 24Full year 2025 earnings releasedFull year 2025 results: Revenue: kr10.8m (up kr10.6m from FY 2024). Net loss: kr14.9m (loss narrowed 90% from FY 2024).
New Risk • Mar 17New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr38m free cash flow). Share price has been highly volatile over the past 3 months (23% average weekly change). Earnings have declined by 5.1% per year over the past 5 years. Shareholders have been substantially diluted in the past year (111% increase in shares outstanding). Revenue is less than US$1m (kr162k revenue, or US$17k). Market cap is less than US$10m (€3.64m market cap, or US$4.19m). Minor Risk Latest financial reports are more than 6 months old (reported June 2025 fiscal period end).
お知らせ • Dec 30CodeLab Capital AS, Annual General Meeting, Jun 23, 2026CodeLab Capital AS, Annual General Meeting, Jun 23, 2026.
お知らせ • Dec 29+ 4 more updatesCodeLab Capital AS to Report Fiscal Year 2025 Final Results on Apr 21, 2026CodeLab Capital AS announced that they will report fiscal year 2025 final results at 4:25 PM, Central European Standard Time on Apr 21, 2026
Board Change • Nov 19No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. CEO & Chairman of the Board Anton Bondesen was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • May 28CodeLab Capital AS announced that it has received fundingCodeLab Capital AS announced a private placement transaction and it has issued 4799998 new shares on May 26, 2025.
お知らせ • May 06CodeLab Capital AS (OB:CODE) signed an agreement to acquire 97.40% stake in Kuba Norge As for NOK 18.5 million.CodeLab Capital AS (OB:CODE) signed an agreement to acquire 97.40% stake in Kuba Norge As for NOK 18.5 million on May 5, 2025. The purchase price is NOK 20 million, to be paid as follows: one third of the purchase price shall be paid in cash at closing of the Transaction, one third of the purchase price shall be paid in kind through the issuance of 1,302,071 consideration shares in CodeLab at Closing, valued at NOK 5.12 per share, one third of the purchase price shall be deferred payment which falls due first quarter of 2028. The deferred payment is subject to adjustment depending on the development of the cash EBITDA of Kuba for 2027, but is capped at 1.5x the original deferred payment. Following the acquisition of Kuba Norge AS, CodeLab Capital AS is adjusting its leadership structure to align with its strategic direction. CEO Kristian Ikast will transition to the role of Chairman of the Board of Directors and continue as a close advisor to the company. CFO Christoffer Mathiesen will remain in his current role. Anton Lorenz Bondesen, the current Chairman of the Board, will become the CEO and will also continue as a member of the Board of Directors. The Transaction is subject to standard closing conditions, including the approval of the Company's shareholders in a general meeting for issuance of the Consideration Shares as well as certain other amendments to the share capital of the Company as described below. CodeLab Capital AS has secured approximately NOK 13.9 million in new equity funding for its acquisition of Kuba Norge AS, with contributions from leading shareholders such as Lorenz AS and Codee Holding AS, as well as other existing shareholders and external investors, including the sellers. The funding is at a subscription price of NOK 3.00 per share. CodeLab plans to conduct a private placement to complete the transaction, with a potential subsequent repair issue for minority shareholders. For the period ending December 31, 2024, Kuba Norge As reported total revenue of NOK 12.5 million. Advokatfirmaet Schjødt As acted as legal advisor to CodeLab Capital AS.
お知らせ • Jan 24CodeLab Capital AS to Report Fiscal Year 2024 Results on May 15, 2025CodeLab Capital AS announced that they will report fiscal year 2024 results at 9:00 AM, Central European Standard Time on May 15, 2025
お知らせ • Jan 02CodeLab Capital AS, Annual General Meeting, Jun 27, 2025CodeLab Capital AS, Annual General Meeting, Jun 27, 2025.
お知らせ • Jan 01+ 1 more updateCodeLab Capital AS to Report Q4, 2025 Results on Feb 20, 2026CodeLab Capital AS announced that they will report Q4, 2025 results on Feb 20, 2026
お知らせ • Jul 24Uniscale, Wholly-Owned Subsidiary of CodeLab Capital, Announces Peter Tuborgh Arnth Nielsen as New Head of Enterprise and PartnershipsUniscale, a wholly-owned subsidiary of CodeLab Capital, announced Peter Tuborgh Arnth Nielsen as the new Head of Enterprise and Partnerships, effective immediately. His role will be crucial in ensuring the growth and development of these strategically important areas of the business. Peter brings extensive experience in building long-term partnerships with international enterprises and large customers.
New Risk • Mar 17New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr150m free cash flow). Shares are highly illiquid. Earnings have declined by 49% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (€18.4m market cap, or US$20.0m).
Board Change • Mar 13No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
お知らせ • Oct 28CodeLab Capital AS to Report Q4, 2023 Results on Feb 23, 2024CodeLab Capital AS announced that they will report Q4, 2023 results on Feb 23, 2024
お知らせ • May 19Jesper Melin Ganc-Petersen acquired an unknown minority stake in PatientSky Group AS.Jesper Melin Ganc-Petersen acquired an unknown minority stake in PatientSky Group AS on May 17, 2023.Jesper Melin Ganc-Petersen completed the acquisition of an unknown minority stake in PatientSky Group AS on May 17, 2023.
Buying Opportunity • May 03Now 81% undervalued after recent price dropOver the last 90 days, the stock is down 65%. The fair value is estimated to be €0.20, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to decline by 0.7% per annum. Earnings is forecast to grow by 36% per annum over the same time period.
Reported Earnings • Mar 06Full year 2022 earnings releasedFull year 2022 results: Revenue: kr194.5m (down 6.8% from FY 2021). Net loss: kr121.3m (loss widened 32% from FY 2021). Revenue is forecast to grow 2.1% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Healthcare Services industry in Europe.
お知らせ • Jan 03+ 5 more updatesPatientSky Group AS to Report Q1, 2023 Results on May 25, 2023PatientSky Group AS announced that they will report Q1, 2023 results on May 25, 2023
Reported Earnings • Nov 16Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: kr46.3m (down 10.0% from 3Q 2021). Net loss: kr29.3m (loss widened 69% from 3Q 2021). Revenue is forecast to stay flat during the next 3 years compared to a 9.9% growth forecast for the Healthcare Services industry in Europe.
Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Investment Director & Director Sven Bakken was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 13Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: kr46.3m (down 11% from 3Q 2021). Net loss: kr29.3m (loss widened 5.1% from 3Q 2021). Revenue is forecast to stay flat during the next 3 years compared to a 9.8% growth forecast for the Healthcare Services industry in Europe.
Reported Earnings • Aug 29Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: kr48.0m (down 6.7% from 2Q 2021). Net loss: kr22.9m (loss widened 26% from 2Q 2021). Over the next year, revenue is expected to shrink by 3.5% compared to a 16% growth forecast for the Healthcare Services industry in Germany.
Buying Opportunity • Jul 01Now 26% undervalued after recent price dropOver the last 90 days, the stock is down 17%. The fair value is estimated to be €0.33, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 30% over the last year. Earnings per share has declined by 291%. For the next 3 years, revenue is forecast to decline by 2.4% per annum. Earnings is forecast to grow by 24% per annum over the same time period.
Reported Earnings • May 21First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: kr50.1m (down 2.9% from 1Q 2021). Net loss: kr28.0m (loss widened 29% from 1Q 2021). Over the next year, revenue is forecast to grow 18%, compared to a 23% growth forecast for the industry in Germany.
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Sven Bakken was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 10+ 2 more updatesPatientSky Group AS to Report First Half, 2022 Results on Aug 15, 2022PatientSky Group AS announced that they will report first half, 2022 results on Aug 15, 2022
お知らせ • Apr 09PatientSky Group AS, Annual General Meeting, Jun 28, 2022PatientSky Group AS, Annual General Meeting, Jun 28, 2022.
Reported Earnings • Feb 24Full year 2021 earnings: Revenues exceed analyst expectationsFull year 2021 results: Revenue: kr210.0m (up 50% from FY 2020). Net loss: kr79.4m (loss widened 239% from FY 2020). Revenue exceeded analyst estimates by 3.4%. Over the next year, revenue is forecast to grow 14%, compared to a 42% growth forecast for the industry in Germany.
お知らせ • Feb 17PatientSky Group AS to Report Q4, 2021 Results on Feb 22, 2022PatientSky Group AS announced that they will report Q4, 2021 results on Feb 22, 2022
Recent Insider Transactions • Sep 04Chief Commercial Officer recently bought €56k worth of stockOn the 1st of September, Egil Noen bought around 150k shares on-market at roughly €0.37 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold €48k more in shares than they bought in the last 12 months.
お知らせ • Feb 19+ 2 more updatesPatientSky Group AS to Report First Half, 2021 Results on Sep 01, 2021PatientSky Group AS announced that they will report first half, 2021 results on Sep 01, 2021
Is New 90 Day High Low • Feb 19New 90-day low: €1.08The company is down 17% from its price of €1.29 on 20 November 2020. The German market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare Services industry, which is up 5.0% over the same period.
Recent Insider Transactions • Jan 30Co-founder & CTO recently sold €104k worth of stockOn the 27th of January, Andreas Kruger sold around 80k shares on-market at roughly €1.29 per share. This was the largest sale by an insider in the last 3 months. This was Andreas' only on-market trade for the last 12 months.
お知らせ • Jan 28+ 1 more updatePatientSky Group AS Announces Executive AppointmentsPatientSky Group AS announced the appointment of Pelle Rosell as Chief Marketing Officer for PatientSky Group and Egil Natvik Noen as Chief Commercial Officer with responsibility for mobile apps.
お知らせ • Dec 04PatientSky Group AS (OB:PSKY-ME) completed the acquisition of Infodoc AS and Acino AS.PatientSky Group AS (OB:PSKY-ME) entered into a conditional share purchase agreement to acquire Infodoc AS and Acino AS for an enterprise value of approx. NOK 280 million on November 9, 2020. The acquisition is of all the shares in Infodoc AS and Acino AS (collectively, Infodec) . The agreed enterprise value of Infodoc in the transaction is approx. NOK 280 million, on a cash-free and debt-free basis and assuming a normalised level of working capital. The purchase price under the transaction is, subject to customary adjustments, expected to be settled in cash upon closing. The completion of the acquisition is subject to customary closing conditions, including, without limitation, that the buyer shall have completed a due diligence review of Infodoc with a satisfactory result to the buyer (in its sole discretion), no material adverse change having occurred, required third party approvals being obtained as well as certain other conditions. The transaction is expected to close during Q4 2020. Advokatfirmaet Thommessen is acting as legal advisor to PatientSky. HLT Advokatfirma AS acted as legal advisor to Infodoc AS. PatientSky Group AS (OB:PSKY-ME) completed the acquisition of Infodoc AS and Acino AS on December 3, 2020.
お知らせ • Nov 11PatientSky Group AS (OB:PSKY-ME) entered into a conditional share purchase agreement to acquire Infodoc AS and Acino AS for an enterprise value of approx. NOK 280 million.PatientSky Group AS (OB:PSKY-ME) entered into a conditional share purchase agreement to acquire Infodoc AS and Acino AS for an enterprise value of approx. NOK 280 million on November 10, 2020. The acquisition is of all the shares in Infodoc AS and Acino AS (collectively, Infodec) . The agreed enterprise value of Infodoc in the transaction is approx. NOK 280 million, on a cash-free and debt-free basis and assuming a normalised level of working capital. The purchase price under the transaction is, subject to customary adjustments, expected to be settled in cash upon closing. The completion of the acquisition is subject to customary closing conditions, including, without limitation, that the buyer shall have completed a due diligence review of Infodoc with a satisfactory result to the buyer (in its sole discretion), no material adverse change having occurred, required third party approvals being obtained as well as certain other conditions. The transaction is expected to close during Q4 2020. Advokatfirmaet Thommessen is acting as legal advisor to PatientSky.
